Multi-Peptide Protocol

Injury Recovery: BPC-157 + TB-500

These compounds are research chemicals. BPC-157 and TB-500 are not approved by the FDA for human use. This protocol is for educational purposes only.
Contraindications — Do Not Use If:

Active cancer or history of malignancy. Both BPC-157 and TB-500 promote angiogenesis and cell proliferation. Preclinical data suggest potential for tumor growth facilitation.[1]

Pregnancy or breastfeeding. No reproductive toxicology data exist for either compound in humans.

Active systemic infection. Immunomodulatory effects may interfere with the body's infection response.

Anticoagulant therapy or bleeding disorders. TB-500 may influence platelet function. Use with caution in patients on warfarin, heparin, or direct oral anticoagulants.[2]

Children and adolescents. No pediatric safety data are available for either compound.

Patients with fibrotic conditions. The wound-healing and growth-factor-modulating properties of these peptides may exacerbate fibrosis in susceptible individuals.

Rationale for Combination

BPC-157 and TB-500 are frequently combined in injury recovery protocols because they target complementary aspects of the tissue repair cascade. The theoretical basis for their combination draws on their distinct but synergistic mechanisms:

BPC-157: Local Tissue Repair

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a partial sequence of human gastric juice protein. Its primary mechanisms relevant to injury recovery include:

  • Angiogenesis promotion: BPC-157 upregulates vascular endothelial growth factor (VEGF) expression and stimulates new blood vessel formation at the injury site, improving local oxygen and nutrient delivery.[3]
  • Nitric oxide system modulation: It interacts with the NO system to promote vasodilation and tissue perfusion, and may counteract the effects of NO-system inhibitors on wound healing.[4]
  • Growth factor upregulation: BPC-157 has been shown to increase expression of growth hormone receptor (GHR) in tendon fibroblasts in animal models.[5]
  • Tendon-to-bone healing: Rat studies demonstrate improved Achilles tendon healing with BPC-157 administration, with greater biomechanical strength at the repair site.[6]

TB-500: Systemic Healing Support

TB-500 (Thymosin Beta-4 fragment, typically the 17-amino acid active region Ac-SDKP) operates through broader systemic mechanisms:

  • Actin regulation: TB-500 sequesters G-actin to promote F-actin polymerization at the cell leading edge, facilitating cell migration to the injury site.[7]
  • Anti-inflammatory effects: It downregulates inflammatory cytokines and modulates the NF-kB pathway, reducing excessive inflammation that can impair healing.[8]
  • Stem cell recruitment: Thymosin beta-4 has been shown to promote cardiac progenitor cell migration in murine models, suggesting a role in stem cell mobilization.[9]
  • Anti-fibrotic properties: In corneal and cardiac injury models, thymosin beta-4 reduced scar formation and fibrosis.[10]
Combination Not Clinically Studied

This protocol is based on the individual compound research for BPC-157 and TB-500. The specific combination of these two peptides has not been studied in any published clinical trial. The rationale for combining them is theoretical, extrapolated from their individual mechanisms. There is no published human safety data for concurrent use.

Per-Component Dosing

The following dosing information reflects commonly reported protocols in the research and clinical compounding literature. Individual responses vary significantly, and dosing should always be guided by a supervising clinician.

Parameter BPC-157 TB-500
Typical dose 250 – 500 mcg 2.0 – 2.5 mg
Frequency Twice daily (AM/PM) Twice per week
Route Subcutaneous, near injury site Subcutaneous, any site (abdomen)
Half-life ~4 hours (estimated) ~6–8 hours (estimated)
Reconstitution Bacteriostatic water Bacteriostatic water
Storage Refrigerated (2–8 °C) Refrigerated (2–8 °C)
Injection Site Note

BPC-157 is typically injected subcutaneously as close to the injury site as practical. For example, for a patellar tendon injury, injection would be in the subcutaneous tissue near the knee. TB-500 acts systemically and does not need to be injected near the injury; the abdomen is the most common site.

Cycle Structure

Loading Phase (Weeks 1–4 to 1–6)

  • BPC-157: 250–500 mcg subcutaneously twice daily (morning and evening), injected near the injury site
  • TB-500: 2.0–2.5 mg subcutaneously twice per week (e.g., Monday and Thursday)
  • Duration: 4–6 weeks, depending on injury severity and response
  • Most practitioners start at the lower end of the dose range and increase only if tolerated and if clinical response is insufficient after 2 weeks

Maintenance Phase (Weeks 5–8 or 7–12)

  • BPC-157: 250 mcg once daily or every other day
  • TB-500: 2.0 mg once per week
  • Gradually taper frequency based on clinical improvement
  • Discontinue when functional goals are met or at a maximum of 12 weeks total

Off-Cycle

  • A minimum 4-week off-cycle is typically recommended between protocol courses
  • Long-term continuous use has not been studied and is not recommended

Monitoring Guidance

Because neither BPC-157 nor TB-500 has been through formal clinical development, monitoring must be particularly vigilant:

What to Track

  • Injury progress: Functional assessment (range of motion, pain scales, strength testing) at baseline, 2 weeks, and 4 weeks
  • Injection site reactions: Redness, swelling, pain, or induration at injection sites. Document and photograph.
  • Blood pressure: BPC-157 may modulate the nitric oxide system, which could affect blood pressure. Monitor at baseline and biweekly.
  • Basic blood work: CBC, CMP, and liver function at baseline and at protocol completion. There is no established hepatotoxicity signal, but monitoring is prudent given the absence of formal safety data.
  • Symptom diary: Daily log of energy, GI symptoms, mood changes, sleep quality, and any new symptoms

When to Stop

  • Any sign of allergic reaction (urticaria, angioedema, anaphylaxis)
  • Persistent injection site reactions that worsen over time
  • New or worsening headaches, vision changes, or neurological symptoms
  • Significant blood pressure changes (>20 mmHg systolic or >10 mmHg diastolic from baseline)
  • Any suspected tumor growth or new mass
  • GI bleeding or unexplained abdominal pain
  • No clinical improvement after 4 weeks at full dose

Side Effects

BPC-157

  • Commonly reported: Mild nausea, dizziness, headache (typically transient, resolving within the first week)
  • Injection site: Redness, swelling, or mild pain at injection site
  • GI effects: Mild GI discomfort if taken orally (less common with subcutaneous route)
  • Theoretical concern: Promotion of angiogenesis could theoretically accelerate tumor vascularization in patients with occult malignancies[1]

TB-500

  • Commonly reported: Fatigue, lethargy, and headache in the first 1–2 days after injection
  • Injection site: Transient redness and mild swelling
  • Flu-like symptoms: Occasionally reported in the first week of use, typically self-limiting
  • Theoretical concern: Thymosin beta-4 has been found at elevated levels in certain cancers, though causality has not been established[11]

Drug Interactions

No formal drug interaction studies have been conducted for either BPC-157 or TB-500. The following are theoretical considerations based on known mechanisms:

  • Anticoagulants (warfarin, heparin, DOACs): TB-500 may have mild anticoagulant-like effects. Concurrent use may increase bleeding risk. Monitor INR more frequently if on warfarin.[2]
  • NSAIDs: BPC-157 has shown cytoprotective effects against NSAID-induced GI damage in animal models, but the clinical significance of this interaction in combination therapy is unknown.[12]
  • Antihypertensives: BPC-157's modulation of the nitric oxide system may potentiate or antagonize blood pressure medications. Monitor blood pressure closely.
  • Immunosuppressants: Both peptides have immunomodulatory properties. Theoretical risk of unpredictable immune effects when combined with cyclosporine, tacrolimus, or corticosteroids.
  • Growth hormone or IGF-1: Additive growth-promoting effects. Use with caution and increased cancer surveillance.

Video Resources

These videos from trusted educators provide additional context on tissue repair peptides and recovery protocols.

BPC-157, TB-500, and healing peptides discussed in depth — Huberman Lab

Dr. Koniver discusses injury recovery peptide protocols — Huberman Lab

References

  1. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Current Pharmaceutical Design. 2014;20(7):1126-1135. doi:10.2174/13816128113190990411. PMID: 23755729.
  2. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta-4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy. 2012;12(1):37-51. doi:10.1517/14712598.2012.634793. PMID: 22074294.
  3. Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Current Neuropharmacology. 2016;14(8):857-865. doi:10.2174/1570159X13666160502153022. PMID: 27138887.
  4. Sikiric P, Seiwerth S, Rucman R, et al. Pentadecapeptide BPC 157 and the NO system. Current Pharmaceutical Design. 2014;20(7):1126-1135. doi:10.2174/13816128113190990411.
  5. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3):774-780. doi:10.1152/japplphysiol.00945.2010. PMID: 21030672.
  6. Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and gastric pentadecapeptide BPC 157 therapy. Journal of Pharmacological Sciences. 2006;100(suppl 1):93P.
  7. Safer D, Elzinga M, Nachmias VT. Thymosin beta-4 and Fx, an actin-sequestering peptide, are indistinguishable. Journal of Biological Chemistry. 1991;266(7):4029-4032. PMID: 1999398.
  8. Sosne G, Qiu P, Christopherson PL, Wheater MK. Thymosin beta-4 suppression of corneal NFkappaB: a potential anti-inflammatory pathway. Experimental Eye Research. 2007;84(4):663-669. doi:10.1016/j.exer.2006.12.004. PMID: 17254565.
  9. Smart N, Risebro CA, Melville AAD, et al. Thymosin beta-4 is essential for coronary vessel development and promotes neovascularization via adult epicardium. Annals of the New York Academy of Sciences. 2007;1112:171-188. doi:10.1196/annals.1415.000. PMID: 17468237.
  10. Sosne G, Szliter EA, Barrett R, Kernacki KA, Kleinman H, Hazlett LD. Thymosin beta-4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Experimental Eye Research. 2002;74(2):293-299. doi:10.1006/exer.2001.1125. PMID: 11950239.
  11. Huang WQ, Wang QR. Bone marrow thymosin beta-4 expression and its relationship with hematopoiesis. Acta Haematologica. 2003;109(2):93-98. doi:10.1159/000068494. PMID: 12624492.
  12. Sikiric P, Seiwerth S, Grabarevic Z, et al. The beneficial effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duodenal lesions induced by restraint stress, cysteamine and 96% ethanol in rats. Journal of Physiology Paris. 1993;87(5):313-327. doi:10.1016/0928-4257(93)90038-U. PMID: 8298610.